GenSight Biologics [SIGHT:PA] €99 MM MCap

Gene ther­a­py: reti­nal & CNS de­gen­er­a­tive patholo­gies and mi­to­chon­drial dis­ease. Fil­ing for MAA exp Q1 2020 in EU and Q4 2020 in US. Op­to­ge­net­ic pro­gram and tar­get­ed dis­ease im­me­di­ate­ly trans­fer­able to dry AMD. Plat­form com­bines mono-ge­net­ic ther­a­py-based ap­proach w core tech­nol­o­gy plat­form and pro­pri­e­tary Mi­to­chon­drial Tar­get­ing Se­quence. [more in­for­ma­tion]